TGF beta 1 and biglycan, decorin, and fibromodulin metabolism in canine cartilage.
OBJECTIVE
Small proteoglycans (PGs) may accumulate in late stage osteoarthritis even as aggrecan is lost. It is not clear what role transforming growth factor (TGF) beta has in this accumulation. Our goal was to investigate the ability of TGF beta 1 to modulate the synthesis and accumulation of decorin, biglycan, and fibromodulin in cartilage explants cultured under conditions in which aggrecan synthesis remains relatively constant.


METHODS
Articular cartilage was cultured in the presence or absence of 4 ng/ml TGF beta 1 for up to 16 days. Material extracted from cartilage was assayed for 35SO(4)-large and small PGs and for total endogenous decorin, biglycan and fibromodulin.


RESULTS
The synthesis of 35SO(4)-small PGs increased during the 16 days in culture in response to TGF beta 1, but declined in control cultures. The difference in 35SO(4)-decorin between TGF beta 1 and control samples reached nine-fold after 16 days, while the difference in total endogenous decorin was less than 1.5-fold. 35SO(4)-decorin, which was present in TGF beta 1-treated cultures had an identical core protein, but a longer glycosaminoglycan chain than that of decorin in control cultures. No significant differences in endogenous biglycan were detected, but accumulation of fibromodulin in TGF beta 1 explants exceeded fibromodulin in controls, on average, by 3.8-fold. Fibromodulin was present in cartilage in both keratan sulfate- and non-sulfated oligosaccharide-substituted forms.


CONCLUSIONS
The accumulation of each of the three small PGs was affected to a different extent in response to TGF beta 1. Of the three, fibromodulin content was most rapidly augmented in response to TGF beta 1.
Burton-Wurster
N
N
James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca,NY 14853, USA. niw1@cornell.edu
Liu
W
W
Matthews
G L
GL
Lust
G
G
Roughley
P J
PJ
Glant
T T
TT
Cs-Szabó
G
G
D000818:Animals; D001345:Autoradiography; D058578:Biglycan; D015153:Blotting, Western / Q000379:methods; D002352:Carrier Proteins / Q000032:analysis / Q000096:biosynthesis / Q000378:metabolism*; D002358:Cartilage, Articular / Q000187:drug effects* / Q000378:metabolism; D002478:Cells, Cultured; D058575:Decorin; D004285:Dogs; D004591:Electrophoresis, Polyacrylamide Gel / Q000379:methods; D016326:Extracellular Matrix Proteins; D000071235:Fibromodulin; D006031:Glycosylation; D008163:Luminescent Measurements; D010003:Osteoarthritis / Q000378:metabolism*; D011509:Proteoglycans / Q000032:analysis / Q000096:biosynthesis / Q000378:metabolism*; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
D058578:Biglycan; D002352:Carrier Proteins; D058575:Decorin; D016326:Extracellular Matrix Proteins; D011509:Proteoglycans; D016212:Transforming Growth Factor beta; D000071235:Fibromodulin